MiniMed’s first-ever tubeless insulin pump, MiniMed Fit, has officially received FDA clearance! The new patch pump brings up to 300 units of insulin, up to seven days of wear, and no cartridge changes, marking a major expansion of Medtronic’s insulin pump lineup. MiniMed expects to begin a phased U.S. rollout in spring 2027.
Fit is entering an increasingly competitive tubeless pump market. Tandem’s tubeless Mobi recently received FDA clearance, offering an infusion site that can last up to seven days, although its insulin cartridge still needs to be changed every three days. Omnipod 5 continues to lead the U.S. tubeless market, while Beta Bionics’s Mint is another upcoming patch pump bringing its own approach to tubeless insulin delivery. With several new options on the horizon, the next year could bring some of the biggest changes the insulin pump market has experienced.
Check out the video above for a closer look at everything we know about MiniMed Fit so far, including its two-piece design, insulin capacity, CGM compatibility, SmartGuard algorithm, waterproof rating, and expected availability. We also break down how Fit compares to other tubeless pump designs and what its arrival could mean for the future of diabetes technology.
Which tubeless pump are you most excited about? Let us know in the comments!
